Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Real-world experience and outcomes of hepatocellular carcinoma (HCC) treated with transarterial radioembolization (TARE).
Authors
Parthib Das
The Ohio State University Wexner Medical Center, Columbus, OH
Parthib Das , Eric Min , Samuel Paul , Ashish Manne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 463)
DOI
10.1200/JCO.2024.42.3_suppl.463
Abstract #
463
Poster Bd #
B8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.
First Author: Arndt Vogel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Impact of etiology of hepatocellular carcinoma on treatment outcomes in a real-world database.
First Author: Timothy J Brown
Poster
2020 ASCO Virtual Scientific Program
Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC).
First Author: Han Sang Kim
Poster
2020 Gastrointestinal Cancers Symposium
Real-world treatment patterns and survival in patients (pts) with hepatocellular carcinoma in the United States.
First Author: Michael Morse